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Abstract
Background: Most malaria rapid diagnostic tests (RDTs) detect Plasmodium falciparum and an antigen common to the 
four species. Plasmodium vivax-specific RDTs target P. vivax-specific parasite lactate dehydrogenase (Pv-pLDH). Previous 
observations of false positive Pv-pLDH test lines in P. falciparum samples incited to the present study, which assessed P. 
vivax-specific RDTs for the occurrence of false positive Pv-pLDH lines in P. falciparum samples.
Methods: Nine P. vivax-specific RDTs were tested with 85 P. falciparum samples of high (≥2%) parasite density. Mixed P. 
falciparum/P. vivax infections were ruled out by real-time PCR. The RDTs included two-band (detecting Pv-pLDH), three-
band (detecting P. falciparum-antigen and Pv-pLDH) and four-band RDTs (detecting P. falciparum, Pv-pLDH and pan-
pLDH).
Results: False positive Pv-pLDH lines were observed in 6/9 RDTs (including two- three- and four-band RDTs). They 
occurred in the individual RDT brands at frequencies ranging from 8.2% to 29.1%. For 19/85 samples, at least two RDT 
brands generated a false positive Pv-pLDH line. Sixteen of 85 (18.8%) false positive lines were of medium or strong line 
intensity. There was no significant relation between false positive results and parasite density or geographic origin of 
the samples.
Conclusion: False positive Pv-pLDH lines in P. falciparum samples with high parasite density occurred in 6/9 P. vivax-
specific RDTs. This is of concern as P. falciparum and P. vivax are co-circulating in many regions. The diagnosis of life-
threatening P. falciparum malaria may be missed (two-band Pv-pLDH RDT), or the patient may be treated incorrectly 
with primaquine (three- or four-band RDTs).
Background
Malaria rapid diagnostic tests (RDTs) are immunochro-
matographic tests targeting antigens of one or more Plas-
modium  species. Signals are visible as cherry-red to
purple coloured lines, comprising a control line (which
indicates that the test has been performed well) and one
or two test lines. The initially developed two band tests
generate a test line that targets P. falciparum by detecting
either histidine-rich protein 2 (HRP-2) or P. falciparum-
specific parasite lactate dehydrogenase (Pf-pLDH). The
later developed three band tests include a second target
that is common to the four Plasmodium species, such as
aldolase or pan-specific parasite lactate dehydrogenase
(pan-pLDH). However, the conventional three-band
RDTs, detecting a P. falciparum-specific antigen and a
pan-Plasmodium antigen, cannot distinguish between a
P. falciparum infection and a mixed infection with P.
vivax when both test lines are observed. Differentiation
between the non-falciparum species is neither possible. P.
falciparum and P. vivax infections require different treat-
ment, which makes discrimination between the two spe-
cies important. RDTs specific to P. vivax could be useful.
There are two-band RDTs that detect Plasmodium vivax-
specific pLDH (Pv-pLDH), three-band RDTs in which
Pv-pLDH is combined with HRP-2 or Pf-pLDH, and so-
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called four-band tests that combine detection of HRP-2,
pan-pLDH and Pv-pLDH. The Pv-pLDH tests have
undergone limited evaluation [1-3].
In previous evaluations of RDTs targeting Pv-pLDH,
rare but consistent false positive Pv-pLDH test lines were
observed among P. falciparum samples, especially at high
parasite densities [2-4]. These observations are of con-
cern as this limits the potential use of the Pv-pLDH
directed RDTs, both in endemic and non-endemic set-
tings. In order to study the extent of this phenomenon
among other RDTs, the present study was undertaken to
challenge available RDT brands with a Pv-pLDH test line
to a panel of P. falciparum samples with high parasite
densities.
Methods
Study design
Several RDTs were retrospectively evaluated in a refer-
ence laboratory on a panel of stored whole blood samples
obtained in patients suspected of malaria. The reference
method was microscopy corrected by polymerase chain
reaction (PCR).
Patient samples
In this study stored whole blood samples (-70°C) were
used, obtained in returned international travelers sus-
pected of malaria presenting at the outpatient depart-
ment of the Institute of Tropical Medicine (ITM),
Antwerp, Belgium, or submitted by other Belgian labora-
tories to ITM in its function of National Reference Cen-
ter. Samples had been obtained between 1996 and 2009
and were classified in regions of travel destinations
according to the United Nations classification of geo-
graphical region and composition [5]. All samples were
evaluated by microscopy and real-time PCR for species
identification (ruling out mixed infections) and determi-
nation of parasite density, as described previously [6,7].
For the purpose of this study, the more convenient para-
site density expressed by % of infected red blood cells was
applied, thereby assuming 50,000/μl to be equal to 1% of
red blood cells parasitized [8]. P. falciparum-infected
samples with parasite densities ≥2% (≥100,000/μl) were
selected.
Malaria rapid diagnostic tests
RDTs containing a P. vivax-specific test line were
selected, including those published on the World Health
Organization (WHO) list of RDT manufacturers with
adequate evidence of good manufacturing [9] as well as
others available on the international market. We checked
the package inserts to ensure the antigen used was P.
vivax-specific. In line with other comparative evaluations
[7,10] it was decided not to display individual RDT brand
names because of the wide lot-to-lot variability and the
frequent changes in composition and brand names and
types [1].
Test procedures
Tests were performed according to the manufacturers'
instructions, except that a pipette (Finnpipette, Helsinki,
Finland) was used instead of the transfer devices supplied
by the manufacturer. The laboratory technicians involved
in the study have received a detailed training and their
performance and agreement are monitored by participa-
tion to internal and external quality control assessments.
R ea dings  w er e  done  by t hr ee  s ubsequ e n t  obse rve rs,  of
whom the first always was the one performing the test,
and carried out at daylight assisted by an electric bulb.
The observers were blinded to each others readings and
to the results of microscopy and PCR. In case no control
line was observed the test was considered invalid and
repeated. Test line intensities were scored according to a
system of five categories as described previously [6]: none
(no line visible), faint (barely visible line), weak (paler
than the control line), medium (equal to the control line)
and strong (stronger than the control line). Test results
were based on consensus agreement: the same test result
observed by at least two out of three readers. In case of no
consensus the result of the first reader was considered.
Pv-pLDH lines generated by P. falciparum samples will be
further referred to as false positive Pv-pLDH lines.
Statistical analysis
The nonparametric Spearman's rank correlation coeffi-
cient rs was used to measure the strength of association
between parasite density and the number of RDTs with a
false positive Pv-pLDH test line. Associations were con-
sidered significant at a p-value < 0.05. Inter-observer
agreement for line intensities and positive and negative
test results were expressed by kappa values for each pair
of observers and by the percentage of overall agreement
between the three observers.
Ethical review
The study was reviewed and approved by the Institutional
Review Board of ITM and by the Ethical Committee of
Antwerp University, Belgium.
Results
Collection of samples and RDTs
Eighty-five P. falciparum samples with a parasite density
≥2% (100,000/μl) were selected. The parasite densities
ranged from 2-35%, with 30 samples of at least 20% para-
site density.
The male:female ratio was 3:1, with a median age of 40
years (range 3-98 years) and three children were under
t h e  a g e  o f  f i v e  y e a r s .  S a m p l e s  w e r e  o b t a i n e d  i n  W e s t
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5), Southern Africa (n = 4) and West Asia (n = 1). Of 19
samples no data on the geographic origin were known
and could not be retrieved. Four RDT brands (numbers.
1, 4, 7 and 9) were tested with less than 85 samples, due to
either a lack of RDTs or a lack of sample.
Twenty different RDT brands were selected. Although
their product name referred to P. vivax-specificity (for
instance, by adding the epithet "Pf/Pv"), two of them in
fact targeted pan-pLDH instead of Pv-pLDH: these RDTs
were not considered for evaluation. Seven companies
marketing eight RDT brands did not reply to the order of
RDTs, despite several reminders via email contact. One P.
vivax-specific three-band RDT was not included in this
study because of bad clearance of the background, which
made reading results impossible. The final panel con-
sisted of nine different RDT brands from seven manufac-
turers, including one two-band (single Pv-pLDH test
line), three three-band (Pv-pLDH and HRP-2 test line)
and five four-band RDTs (Pv-pLDH, HRP-2 and pan-
pLDH test line). Five RDTs had CE mark compliance and
two were included in the WHO list of good manufactur-
ing practices.
Three different four-band RDT brands (numbers 6, 7
and 8) had similar package inserts and the cassettes had
identical morphology. Two three-band RDTs (numbers. 2
and 3) also had identical cassettes and similar package
inserts. RDT numbers 1 and 4 were from the same manu-
facturer, as well as RDT numbers 2 and 5.
Test characteristics
There were no invalid test results. As expected, all the P.
falciparum  samples showed positive test lines for the
HRP-2 and the pan-pLDH test lines, if present on the cas-
sette. Table 1 lists the results for the Pv-pLDH test lines,
expressed by line intensities. In total there were 85 false
positive Pv-pLDH lines in six RDT brands, caused by a
total of 42 samples. In the individual RDT brands they
occurred at frequencies of 8.2% (7/85 samples) up to
29.1% (23/79 samples), among two-, three- and four-band
tests. There was no difference between RDTs that were
CE-marked or WHO-listed and those which were not.
Table 2 lists the details of consensus readings of line
intensities for the false positive Pv-pLDH test lines,
according to parasite densities and region of infection. In
2/736 readings there was no consensus and the results of
the first reader were considered. Nineteen samples gener-
ated a false positive line in at least two RDTs. There was
no apparent relation between parasite density of samples
and the occurrence of false positive Pv-pLDH lines (rs =
0,155, p = 0,153). False-positive Pv-pLDH lines occurred
exclusively in samples from patients returning from Mid-
dle or West Africa (Table 3), but there was no significant
relation between geographic origin of samples and false-
positive results.
Most (69/85, 81.2%) false-positive Pv-pLDH readings
were faint or weak (T able 1), but strong line intensities
were observed in two RDT brands (Tables 1 and 2). Taken
all readings together, inter-observer agreements for line
intensity readings were good for HRP-2, pan-pLDH and
Pv-pLDH test lines. For the Pv-pLDH line, in terms of
positive and negative readings for all brands together,
kappa values between pairs of observers were good (0.79,
0.70, 0.77) and overall agreement was excellent (88.0%).
For the RDT brands considered separately, overall agree-
ment for the Pv-pLDH line ranged from 75.9% to 100%.
Discussion
In this study, six out of nine P. vivax-specific RDTs
showed false positive Pv-pLDH lines when challenged to
a panel of 85 P. falciparum samples with high (≥2%) para-
site densities, in which mixed infections with P. vivax
Table 1: Line intensity reading for Pv-pLDH lines in P. falciparum samples with parasite densities ≥2%
Line intensity readings, number of samples
Nr Type Nr of samples tested Faint Weak Medium Strong Total positive (% of total samples)
1 Two-band 84 7 4 1 4 16 (19.0%)
2 Three-band 85 0
3 Three-band 85 0
4 Three-band 66 2 5 4 11 (16.7%)
5F o u r - b a n d 8 5 0
6 Four-band 85 8 13 21 (24.7%)
7 Four-band 79 19 3 1 23 (29.1%)
8F o u r - b a n d 8 5 2 5 7  ( 8 . 2 % )
9F o u r - b a n d 8 2 1 5 1 7  ( 8 . 5 % )
Two-band: Pv-pLDH test line; Three-band: Pv-pLDH and HRP-2 test line; Four-band: Pv-pLDH, HRP-2 and pan-pLDH test line.Maltha et al. Malaria Journal 2010, 9:198
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Table 2: False positive Pv-pLDH lines in 42 P. falciparum samples with parasite densities ≥2%
Samples RDT number and type
Nr % parasite 
density
Origin 1. Two-band 4. Three-band 6. Four-band 7. Four-band 8. Four-band 9. Four-band Total RDTs 
positive
1 2 , 0 M A F -- --- W 1
2 2 , 2 M A F -*F---1
3 2 , 3 M A F -*W ---1
4 2 , 8 W A F FF----2
5 3 , 2 M A F W S WWWW 6
63 , 2M A F - * - F F - 2
7 3 , 3 W A F -*F---1
8 3 , 7 N D S* -F--2
9 3 , 8 N D -- -F--1
1 0 3 , 9 N D --W F--2
11 4,0 WAF S S W F W - 5
1 2 4 , 2 W A F W M----2
1 3 4 , 5 W A F FF----2
1 4 4 , 6 M A F --F---1
1 5 5 , 3 W A F M M W F--4
1 6 5 , 5 W A F -- -F--1
17 5,7 MAF S S W W - F 5
1 8 6 , 6 M A F F* ----1
1 9 7 , 0 N D --W F--2
20 7,2 WAF S * W M W M 5
2 1 7 , 4 W A F -- -F--1
2 2 7 , 6 M A F -- -F--1
2 3 9 , 1 N D -- --- W 1
2 4 9 , 6 N D *M W F--3
2 5 2 0 , 0 N D -- -F--1
2 6 2 0 , 0 W A F F- -F--2
2 7 2 0 , 0 W A F --W ---1
28 20,0 WAF W S W F W - 5
29 20,0 WAF W M F F - W 5
3 0 2 0 , 0 W A F --FF--2
3 1 2 0 , 0 N D F- ----1
3 2 2 0 , 0 N D F- -F--2
3 3 2 0 , 0 W A F -- -F--1
3 4 2 0 , 0 M A F -* --- W 1
3 5 2 0 , 0 N D -*F---1
3 6 2 0 , 0 M A F F* ----1
3 7 2 0 , 0 W A F -*W ---1
3 8 2 0 , 0 W A F -*F---1
3 9 2 0 , 0 W A F -*F---1
4 0 2 0 , 0 M A F -- -F--1
4 1 2 0 , 0 W A F - M WWW - 4Maltha et al. Malaria Journal 2010, 9:198
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were excluded by PCR analysis. Frequencies for individ-
ual brands ranged from 8.2% (7/85 samples) to 29.1% (23/
79 samples).
Plasmodium vivax accounts for almost half of the
malaria infections worldwide and is no longer considered
as a mild infection: complicated infections have been
demonstrated in both endemic countries and in returned
travelers [11,12]. In addition, P. vivax malaria may be
chloroquine resistant and has a tendency to relapse [13].
To eradicate the dormant liver stages, primaquine treat-
ment is needed. Primaquine is contraindicated in case of
glucose-6-phosphate dehydrogenase (G6PD) deficiency,
due to the risk of hemolysis [14,15]. G6PD deficiency is
common in most P. vivax malaria areas; moreover, in
these areas G6PD testing is impractical due to a lack of
funds, equipments or expertise [16].
RDTs detecting P. vivax-specific pLDH are of addi-
tional value for the diagnosis of malaria in both P. vivax
endemic areas and in the setting of travel medicine. The
conventional three-band RDTs detecting a P. falciparum-
specific antigen and a pan-Plasmodium antigen cannot
distinguish between a P. falciparum infection and a mixed
infection with P. vivax when both test lines are observed.
Differentiation between the non-falciparum  species is
neither possible. Three- or four-band RDTs that target
Pv-pLDH have the advantage that they can detect P. vivax
in mixed infections: they are an adjunct to microscopy as
P. vivax is often microscopically under diagnosed in
mixed infections [13]. In addition they can be used to dis-
tinguish between Plasmodium ovale and P. vivax [2]. This
is an advantage in the non-endemic setting, where micro-
scopic differentiation between P. ovale and  P. vivax is
notoriously difficult [17].
Plasmodium vivax-specific RDTs have hardly been
evaluated [18-22], and are not discussed in any of the
recent reviews on malaria RDTs [1,8,17,23]. The present
findings are of concern particularly in areas where P. fal-
ciparum and P. vivax are co-circulating: in case of a two-
band Pv-pLDH test, the diagnosis of life-threatening P.
falciparum malaria may be missed, which is especially of
concern in remote areas among less experienced staff and
without backup of microscopy. In case of a three- or four-
band RDT, the patient may be treated incorrectly with
primaquine, leading to severe hemolysis in patients with
G6PD-deficiency.
Among the limitations of the present study, we should
mention its retrospective nature (precluding further
work-up of samples), the test conditions in a reference
laboratory (which are more favorable than those in field
settings) and the fact that all but one P. falciparum sam-
ples were obtained in travelers returning from Africa. In
addition, the present study explored false positive Pv-
42 35,0 WAF - * - - F - 1
Total false positive Pv-
pLDH lines
16 11 21 23 7 7 85
MAF = Middle Africa; WAF = West Africa; ND = No Data
F = faint; W = weak; M = medium; S = strong; - = negative; * = sample not tested due to lack of RDT or sample
Table 2: False positive Pv-pLDH lines in 42 P. falciparum samples with parasite densities ≥2% (Continued)
Table 3: Numbers of P. falciparum samples generating false positive Pv-pLDH lines according to geographic origin
Numbers of samples tested*
Origin (region) Total Negative Positive** (% of total 
samples)
E a s t  A f r i c a 550
Middle Africa 22 10 12 (54.5)
S o u t h e r n  A f r i c a440
West Africa 34 14 20 (58.8)
W e s t  A s i a 110
No data 19 9 10 (52.6)
All samples 85 43 42 (49.4)
* Nine RDT brands were tested with a panel of 85 samples
** Defined as a sample with a false positive Pv-pLDH line in ≥1 RDT brandMaltha et al. Malaria Journal 2010, 9:198
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pLDH lines exclusively in samples with high P. falciparum
parasite densities, in line with the previous observations
[2-4]. However, the inclusion of P. falciparum samples of
lower parasite density and Plasmodium negative samples
would have completed the picture. A prospective study in
an area with P. falciparum and  P. vivax coexistence
should be performed to assess the relevance of the false
positive Pv-pLDH lines in a field setting.
False-positive reactions of P. vivax samples with the
HRP-2 line and the Pf-pLDH line have been described
previously [24-26], but the presently observed false-posi-
tive Pv-pLDH lines in P. falciparum samples have only
been reported anecdotally [2-4,22]. Among the panel of
RDTs tested in the WHO and Foundation for Innovative
New Diagnostics (FIND) study, there were two RDTs
with a Pv-pLDH line: according to the tables, one of them
generated false positive Pv-pLDH lines in 1.9% (6/316) of
the P. falciparum samples tested.
Without exact knowledge of the antibodies targeting
the Pv-pLDH antigen, it is difficult to explain the phe-
nomenon, especially since false positive Pv-pLDH lines in
the present study occurred not consistently among the
different samples and brands. Weak cross-reactions may
also be facilitated by slight differences in the composition
of the nitrocellulose membrane and the diluent. It is
known that several companies use the same pLDH anti-
bodies in their RDT brands [27] and this may also be the
case for Pv-pLDH: this is reflected by the identical prod-
uct presentations and similar false positive rates of RDT
brands numbers 6 and 7 and numbers 2 and 3 respec-
tively. In the present study, there was no apparent relation
between the false positive Pv-pLDH lines and the geo-
graphic origin of the infection, but it should be noted that
mainly samples from sub-Saharan Africa were included.
The present study also revealed problems in RDT avail-
ability and communication with the supplier in the inter-
national market, as eight brands were not delivered
despite several reminders. Furthermore, two of the RDTs
that claimed to be P. vivax-specific by their label and
name proved to detect pan-pLDH according to their
package insert. Similar confusing names have been noted
previously, also for the antibodies targeting aldolase [28].
Conclusion
The occurrence of false positive Pv-pLDH lines in P. falci-
parum samples with high parasite densities was observed
in six out of nine P. vivax-specific RDTs, in two-, three-
and four-band RDTs. The false positive Pv-pLDH lines
are of concern because the diagnosis of life-threatening P.
falciparum malaria may be missed (two-band Pv-pLDH
RDT), or the patient will be treated incorrectly with pri-
maquine (three- or four-band RDT), which may cause
severe hemolysis in patients with G6PD-deficiency. A
prospective study in an area with P. falciparum and P.
vivax coexistence should be performed to assess the rele-
vance of the false positive Pv-pLDH lines in a field set-
ting.
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